Alamar Biosciences, Inc.’s Post

Measuring IL-17A at ultra-low levels is vital for autoimmune and inflammatory disorder research. Simoa® technology offers unparalleled sensitivity for precise monitoring. Learn more about IL-17A Advantage Plus here ➡️ #Immunology #Oncology #Biomarkers

Measuring IL-17A at ultra-low levels is vital for autoimmune and inflammatory disorder research. Simoa® technology offers unparalleled sensitivity for precise monitoring. Learn more about IL-17A Advantage Plus here ➡️ #Immunology #Oncology #Biomarkers

At #Quanterix we are committed to deliver the right solution for a large numbers of important applications providing the best performance to our users. This is our focus, this is what we believe in… Ask for more… #Quanterix #SIMOA #biomarker #proteomics #neurology #neurodisease #inflammatory #immunology #diagnosys #Dx #alzheimerdisease #parkinson #ultrasensitivity

Measuring IL-17A at ultra-low levels is vital for autoimmune and inflammatory disorder research. Simoa® technology offers unparalleled sensitivity for precise monitoring. Learn more about IL-17A Advantage Plus here ➡️ #Immunology #Oncology #Biomarkers

🍃Our September Issue is live☔️ 📘Cover: The interplay of cancer cachexia and ageing with focus on biomarkers in disease progression 🔎Check out the new EACR Viewpoint 👇 https://buff.ly/4glqBTF

Tracking vesicular proteomic signatures of Hepatitis B virus-Hepatocellular carcinoma: in this work, Lin Cao, Zengqi Tan at Northwest University Xi'an and collaborators assessed multiple methods for small EV isolation and ultimately optimised the use of polysaccharide chitosan-based magnetic beads to separate small EVs from serum samples of healthy controls, as well as patients with chronic hepatitis B infection, liver cirrhosis, and HBV-HCC https://lnkd.in/esaXkMw7 CS-coated bead-isolated EVs were analysed using data-independent acquisition mass spectrometry, followed by cancer trajectory analysis. Machine learning techniques were employed to identify vesicular biomarker signatures specific to HBV-HCC. An article co-authored by Yue Zhou, Shuai Lin, Chunyan Yang, Zixuan Guan, Xiaofan Li, Shujie Yang, Tong Gao, Jiazhen Zhao, Ning Fan, Yanan Song, Dongmin Li, Xiang Li, Zhuo Li and Feng Guan #extracellularvesicles #exosomes #proteomics #liquidbiopsy #livercancer #Vesiculab

At Owlstone Medical our goal is to save 100,000 lives and $1.5B in healthcare costs 🌐 To achieve this goal, we are using our Breath Biopsy platform to identify biomarkers in exhaled breath to detect cancer, inflammatory and infectious diseases. Through this work, we are developing the Breath Biopsy VOC Atlas, a catalogue of identified and quantified VOCs found in exhaled breath. The Atlas provides insight and scientific context to identified compounds enabling more confident selection of candidate biomarkers for a variety of diseases. The goal is to provide a standardized resource that researchers and clinicians can use to compare breath samples, facilitating the identification of biomarkers that are indicative of specific diseases. By building this atlas, we aim to streamline the process of discovering new biomarkers and enhance the accuracy of breath-based diagnostics. To be the first to know when access is available to our soon-to-launch Atlas, join the waitlist today 🔗 https://lnkd.in/eD8Vvdgh #BreathBiopsy #VOCAtlas

📃Scientific paper: Characterizing the kinetics of presepsin and associated inflammatory biomarkers in human endotoxemia Abstract: In this study, we describe the kinetics of a new potential inflammatory biomarker, presepsin, together with a panel of well-established biomarkers in a human endotoxemia study. We evaluated biomarker correlations and identified combinations that could hold valuable insights regarding the state of infection. Continued on ES/IODE ➡️ https://etcse.fr/5Fjb ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

What do the new #EAUGuidelines recommend for non-muscle invasive #bladdercancer (NMIBC)? In this interview, UROONCO BCa chief editor Dr. Benjamin Pradere and Prof. Paolo Gontero provided the latest updates and covered topics such as the substaging of T1 disease, the MBlock technique, treatment options, follow-up cystoscopy, biomarkers, and active surveillance. In addition, the new guidelines also includes a new chapter on quality indicators to bolster care for NMIBC patients. 👇

📅 Save the Date! Don’t miss Professor Harry Sokol, co-founder of Exeliom, speaking at the 16th World Congress on Inflammation from July 21-24 in Quebec. 🇨🇦 🔬 This congress gathers leading experts to discuss the important advances in inflammation science, featuring keynote presentations, workshops, and panel discussions on the latest research and therapeutic strategies. 💡 Professor Sokol will present on Exeliom's pioneering lead candidate, EXL01, which harnesses microbiome-associated innate immune regulatory mechanisms to enhance patient responses in conditions where dysregulated immunity impedes treatment efficacy. By leveraging these mechanisms, EXL01 can be used as a stand-alone or adjuvant treatment to combat inflammation in a variety of conditions including inflammatory bowel diseases, solid tumor cancers, and certain infectious diseases. 🔍 Explore the potential benefits of Exeliom’s approach to improve patient outcomes with Harry’s insights from the congress. https://ow.ly/KsTr50SC80n #Inflammation #HealthcareInnovation #Microbiome #Research